Basil Roufogalis holds the D.S., M.S., and Ph.D. degrees. He has been part of the University of Sydney, Sydney, NSW, Australia, over the course of 20 years. He has been a Professor at the University of British Columbia, Vancouver, BC, Canada, before joining the University of Sydney as a Professor of pharmaceutical chemistry. He has been the Head of the Department of Pharmacy, the Director of the Herbal Medicines Research and Education Centre, and the Professor Dean at the Faculty of Pharmacy, University of Sydney, Australia. His major research interests include calcium translocating ATPase pumps and inhibitors, multidrug resistance in cancer, calcium regulation of cellular signalling by GTP-binding proteins, mechanisms of herbal medicines, and new therapeutic agents from medicinal herbs in pain, diabetes, hyperlipidemia and cancer, and herb-drug interactions. Roufogalis has done extensive research in various herbal medicines and has shown the ability of various extracts in lowering glucose and improving glucose tolerance in various type 2 diabetes models. Furthermore, the ability of these extracts, in some cases their isolated active constituents, has been investigated on preventing the complications of diabetes, including cardiac fibrosis and liver steatosis, using gene transcription and translation techniques together with functional studies. Important mechanisms elucidated include interaction with PPAR-gamma receptors, modulation of iNOS, NFkB, and FATP genes and their protein products, and the alpha-glucosidase enzyme responsible for postprandial hyperglycemia. He also has original work in the prevention of diabetic retinopathy which is being studied in a retinal epithelial cell line. Taurine, a major component of Goji berry, has been found to activate PPAR-gamma and to alter apoptosis and junctional permeability in these retinal cells.
Biography Updated on 26 November 2013